Plasma Cardiotrophin‐1 Levels are Associated With Hypertensive Heart Disease: A Meta‐Analysis
Open Access
- 23 July 2014
- journal article
- review article
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 16 (9), 686-692
- https://doi.org/10.1111/jch.12376
Abstract
Cardiotrophin‐1 (CT ‐1) is a member of the interleukin 6 cytokine superfamily. Plasma CT ‐1 levels have been associated with heart failure and hypertension in small independent studies. Whether plasma CT ‐1 levels are associated with progression of hypertensive heart disease is poorly understood. The authors carried out a meta‐analysis using published studies and electronic databases. Relevant data were extracted using standardized algorithms. Additional data were obtained directly from investigators when indicated. A total of 18 studies were included that reported on association between CT ‐1 level and hypertension (n=8), cardiac hypertrophy (n=9), and heart failure (HF ) (n=10). The serum levels of CT ‐1 were significantly higher in patients with hypertension (standard mean difference [SMD ], 0.85; 95% confidence interval [CI], 0.64–1.06 fmol/mL), left ventricular hypertrophy (SMD, 0.88; 95% CI 0.60–1.17 fmol/mL), or HF (SMD , 0.66; 95% CI , 0.51–0.80 fmol/mL) compared with controls. Subgroup analysis revealed CT ‐1 levels to be highest in patients with hypertension‐induced hypertrophy with HF , followed by patients with hypertension‐induced left ventricular hypertrophy without HF (SMD, 0.52; 95% CI, 0.30–0.75 fmol/mL), patients with hypertension without left ventricular hypertrophy (SMD, 0.67; 95% CI, 0.46–0.88 fmol/mL) as compared with normotensive patients (SMD, 0.74; 95% CI, 10.45–1.04 fmol/mL). Increased plasma CT ‐1 levels are associated with risk for HF in hypertensive patients. CT ‐1 may serve as a novel biomarker in determining prognosis in hypertensive patients.Funding Information
- National Institutes of Health Grant (R01HL094784-05)
This publication has 45 references indexed in Scilit:
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESCEuropean Heart Journal, 2012
- Cardiotrophin-1 plasma levels are increased in patients with diastolic heart failureMedical Science Monitor, 2012
- Epidemiology and risk profile of heart failureNature Reviews Cardiology, 2010
- Cardiotrophin-1 plasma levels are associated with the severity of hypertrophy in hypertrophic cardiomyopathyEuropean Heart Journal, 2010
- Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analysesEuropean Journal of Epidemiology, 2010
- Measuring inconsistency in meta-analysesBMJ, 2003
- Quantifying heterogeneity in a meta-analysisStatistics in Medicine, 2002
- Hypoxic Stress Induces Cardiotrophin-1 Expression in Cardiac MyocytesBiochemical and Biophysical Research Communications, 1999
- An Immunoluminometric Assay for Cardiotrophin-1: A Newly Identified Cytokine Is Present in Normal Human Plasma and Is Increased in Heart FailureBiochemical and Biophysical Research Communications, 1999
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986